Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

2021343 citationsJournal Articlebronze Open Access

Authors

Samer Gawrieh · Indiana University School of Medicine

Mazen Noureddin · Cedars-Sinai Medical Center

Nicole Loo · Texas Liver Institute

Rizwana Mohseni · Catalina Research Institute

Vivek Awasty · Marion General Hospital

Kenneth Cusi · University of Florida Health

Kris V. Kowdley

Abstract

Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).

Topics & Keywords

Liver Disease Diagnosis and Treatment Diet, Metabolism, and Disease Lipid metabolism and disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology

Volume 74, Issue 4, pp. 1809-1824

DOI: 10.1002/hep.31843

Field-Weighted Citation Impact: 37.51